SAREPTA THERAPEUTICS, INC. (SRPT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $6.10B; Treasury Stock, ValueUSD $25.26M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $6.08B; Treasury Stock, ValueUSD $25.26M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $6.04B; Treasury Stock, ValueUSD $25.26M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $5.99B; Treasury Stock, ValueUSD $25.26M.
SAREPTA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Additional Paid in Capital USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $11.00K | $6.10B | $25.26M | $-565.00K | $-4.55B | $1.53B | 655.64K | 3 month · $28.03M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $11.00K | $6.08B | $25.26M | $-121.00K | $-4.55B | $1.51B | 655.64K | 3 month · $33.67M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $11.00K | $6.04B | $25.26M | $272.00K | $-4.88B | $1.14B | 650.88K | 12 month · $139.08M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $11.00K | $5.99B | $25.26M | $220.00K | $-4.64B | $1.32B | 650.88K | 3 month · $16.40M | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $10.00K | $5.84B | $25.26M | $-51.00K | $-4.46B | $1.40B | 650.88K | 3 month · $41.62M | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $10.00K | $5.80B | (m) | $34.00K | $-4.66B | $1.19B | (m) | 3 month · $46.56M | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $10.00K | $5.74B | $0.00 | $-218.00K | $-4.21B | $1.53B | 0.00 | 12 month · $205.13M | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $10.00K | $5.59B | (m) | $2.25M | $-4.37B | $1.22B | (m) | 3 month · $49.00M | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $10.00K | $5.48B | (m) | $-1.03M | $-4.40B | $1.08B | (m) | 3 month · $55.65M | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $9.00K | $5.37B | (m) | $-691.00K | $-4.41B | $961.19M | (m) | 3 month · $45.20M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $9.00K | $5.30B | (m) | $918.00K | $-4.45B | $859.34M | (m) | 12 month · $182.51M | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $9.00K | $5.26B | (m) | $-638.00K | $-4.49B | $764.36M | (m) | 3 month · $48.06M | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $9.00K | $5.19B | (m) | $-1.05M | $-4.45B | $741.41M | (m) | 3 month · $47.38M | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $9.00K | $5.14B | (m) | $-419.00K | $-4.43B | $712.75M | (m) | 3 month · $41.25M | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $9.00K | $4.30B | (m) | $-1.66M | $-3.91B | $384.95M | (m) | 12 month · $233.02M | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $9.00K | $4.24B | (m) | $-3.21M | $-3.80B | $430.84M | (m) | 3 month · $50.42M | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $9.00K | $4.27B | (m) | $-2.48M | $-3.54B | $726.46M | (m) | 3 month · $102.89M | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $9.00K | $4.17B | (m) | $-306.00K | $-3.31B | $856.89M | (m) | 3 month · $29.20M | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $9.00K | $4.13B | (m) | $-20.00K | $-3.21B | $928.01M | (m) | 12 month · $113.94M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $8.00K | $3.55B | (m) | $-20.00K | $-3.08B | $469.53M | (m) | 3 month · $26.68M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $8.00K | $3.52B | (m) | $2.00K | $-3.04B | $485.11M | (m) | 3 month · $28.97M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $8.00K | $3.49B | (m) | $-3.00K | $-2.96B | $535.45M | (m) | 3 month · $28.51M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $8.00K | $3.61B | (m) | $3.00K | $-2.85B | $761.76M | (m) | 12 month · $108.07M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $8.00K | $3.55B | (m) | $-6.00K | $-2.66B | $892.05M | (m) | 3 month · $26.90M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $8.00K | $3.51B | (m) | $6.00K | $-2.46B | $1.04B | (m) | 3 month · $27.62M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $8.00K | $3.46B | (m) | $624.00K | $-2.31B | $1.14B | (m) | 3 month · $24.02M | (m) | (m) | (m) |
| 2020-02-29 | (m) | $312.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $8.00K | $3.11B | (m) | $50.00K | $-2.29B | $818.19M | (m) | 12 month · $78.60M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $7.00K | $3.05B | (m) | $75.00K | $-2.06B | $995.20M | (m) | 3 month · $20.64M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $7.00K | $3.03B | (m) | $82.00K | $-1.93B | $1.10B | (m) | 3 month · $19.76M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $7.00K | $3.00B | (m) | $19.00K | $-1.66B | $1.35B | (m) | 3 month · $16.14M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $7.00K | $2.61B | (m) | $-99.00K | $-1.58B | $1.03B | (m) | 12 month · $50.13M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $7.00K | $2.08B | (m) | $8.00K | $-1.44B | $639.85M | (m) | 3 month · $11.48M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.00K | $2.06B | (m) | $-361.00K | $-1.36B | $699.05M | (m) | 3 month · $15.28M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $7.00K | $2.03B | (m) | $-643.00K | $-1.25B | $776.76M | (m) | 3 month · $10.53M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.00K | $2.01B | (m) | $-379.00K | $-1.22B | $789.22M | (m) | 12 month · $30.46M | (m) | (m) | 12 month · $156.95M |
| 2017-09-30 | (m) | $6.00K | $1.89B | (m) | $-12.00K | $-1.19B | $697.16M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $6.00K | $1.52B | (m) | $-38.00K | $-1.15B | $377.77M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $5.00K | $1.51B | (m) | $-55.00K | $-1.08B | $429.14M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $5.00K | $1.50B | (m) | $-120.00K | $-1.17B | $336.69M | (m) | 12 month · $30.11M | (m) | $336.69M | (m) |
| 2016-09-30 | (m) | $5.00K | $1.49B | (m) | (m) | $-1.08B | $408.62M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $5.00K | $1.14B | (m) | $1.00K | $-1.02B | $121.46M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $5.00K | $1.10B | (m) | $-5.00K | $-958.83M | $138.96M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $5.00K | $1.09B | (m) | $-111.00K | $-899.05M | $190.35M | (m) | 12 month · $32.12M | (m) | $190.35M | (m) |
| 2015-09-30 | (m) | $4.00K | $957.61M | (m) | $-1.00K | $-834.37M | $123.24M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $4.00K | (m) | (m) | $-19.00K | $-782.43M | $165.38M | (m) | (m) | $947.83M | (m) | (m) |
| 2015-03-31 | (m) | $4.00K | (m) | (m) | $-17.00K | $-740.58M | $200.76M | (m) | (m) | $941.36M | (m) | (m) |
| 2014-12-31 | (m) | $4.00K | $926.77M | (m) | $-95.00K | $-679.02M | $247.65M | (m) | 12 month · $20.34M | $926.77M | $247.65M | (m) |
| 2014-09-30 | $0.00 | $4.00K | (m) | (m) | $-55.00K | $-634.61M | $286.20M | (m) | (m) | $920.86M | (m) | (m) |
| 2014-06-30 | $0.00 | $4.00K | (m) | (m) | $-35.00K | $-605.38M | $299.92M | (m) | (m) | $905.34M | (m) | (m) |
| 2014-03-31 | (m) | $4.00K | (m) | (m) | $59.00K | (m) | $228.96M | (m) | (m) | $800.53M | (m) | (m) |
| 2013-12-31 | $0.00 | $4.00K | (m) | (m) | $0.00 | $-543.24M | $247.19M | (m) | 12 month · $11.13M | $790.42M | $247.19M | (m) |
| 2013-09-30 | (m) | $4.00K | (m) | (m) | (m) | (m) | $246.98M | (m) | (m) | $781.40M | (m) | (m) |
| 2013-06-30 | (m) | $3.00K | (m) | (m) | (m) | (m) | $88.82M | (m) | (m) | $581.20M | (m) | (m) |
| 2013-03-31 | (m) | $3.00K | (m) | (m) | (m) | (m) | $87.28M | (m) | (m) | $560.61M | (m) | (m) |
| 2012-12-31 | $0.00 | $3.00K | (m) | (m) | (m) | (m) | $123.68M | (m) | 12 month · $3.08M | $554.93M | $123.68M | (m) |
| 2012-09-30 | $0.00 | $2.00K | (m) | (m) | (m) | (m) | $-4.57M | (m) | (m) | $364.62M | (m) | (m) |
| 2012-06-30 | $0.00 | $2.00K | (m) | (m) | (m) | (m) | $22.50M | (m) | (m) | $342.13M | (m) | (m) |
| 2012-03-31 | $0.00 | $13.00K | (m) | (m) | (m) | (m) | $14.02M | (m) | (m) | $341.68M | (m) | (m) |
| 2011-12-31 | $0.00 | $2.00K | (m) | (m) | (m) | (m) | $31.02M | (m) | 12 month · $3.13M | $340.98M | $31.02M | (m) |
| 2011-09-30 | (m) | $13.00K | (m) | (m) | (m) | (m) | $31.75M | (m) | (m) | $340.29M | (m) | (m) |
| 2011-06-30 | (m) | $14.00K | (m) | (m) | (m) | (m) | $35.15M | (m) | (m) | $339.67M | (m) | (m) |
| 2010-12-31 | (m) | $11.00K | (m) | (m) | (m) | (m) | $-2.82M | (m) | 365 month · $21.42M | $304.82M | $-2.82M | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $23.63M | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.73M | (m) |
| 1980-07-21 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |